Payment overview · 2025
General Payments
$77.69
4 reported records · 3 companies
Healthcare provider profile · identity verified
Denise E Aamodt, MD
Allopathic & Osteopathic Physicians|Family Medicine · RIO RANCHO, NM · NPI 1336172998
Verified facts
What the public records show
CMS Open Payments records show Denise E Aamodt, MD received $77.69 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 48.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.49 | 48.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.47 | 30.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.73 | 21.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $77.69 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 704 | 203 |
| Atorvastatin Calcium | Atorvastatin Calcium | 636 | 196 |
| Lisinopril | Lisinopril | 431 | 131 |
| Losartan Potassium | Losartan Potassium | 338 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 98 |
| Omeprazole | Omeprazole | 286 | 89 |
| Gabapentin | Gabapentin | 277 | 96 |
| Metformin Hcl | Metformin Hcl | 220 | 69 |
| Famotidine | Famotidine | 214 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 199 | 57 |
| Montelukast Sodium | Montelukast Sodium | 191 | 63 |
| Trazodone Hcl | Trazodone Hcl | 181 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 60 |
| Simvastatin | Simvastatin | 166 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 30 |
| Furosemide | Furosemide | 133 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 130 | 17 |
| Carvedilol | Carvedilol | 123 | 37 |
| Trulicity | Dulaglutide | 110 | 20 |
| Allopurinol | Allopurinol | 105 | 31 |
| Buspirone Hcl | Buspirone Hcl | 103 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 22 |
| Lovastatin | Lovastatin | 100 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 28 |
| Ozempic | Semaglutide | 98 | 24 |
| Spironolactone | Spironolactone | 96 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 29 |
| Potassium Chloride | Potassium Chloride | 84 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 43 |
| Eliquis | Apixaban | 81 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 22 |
| Bupropion Xl | Bupropion Hcl | 78 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 23 |
| Pregabalin | Pregabalin | 78 | 21 |
| Mirtazapine | Mirtazapine | 77 | 24 |
| Estradiol | Estradiol | 76 | 34 |
| Lorazepam | Lorazepam | 76 | 23 |
| Atenolol | Atenolol | 72 | 23 |
| Meloxicam | Meloxicam | 72 | 23 |
| Tramadol Hcl | Tramadol Hcl | 70 | 18 |
| Alendronate Sodium | Alendronate Sodium | 69 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 22 |
| Prednisone | Prednisone | 66 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 21 |
| Sertraline Hcl | Sertraline Hcl | 63 | 24 |
| Acyclovir | Acyclovir | 59 | 26 |
| Glipizide | Glipizide | 58 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 21 |
| Metformin Hcl Er | Metformin Hcl | 58 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 13 |
| Baclofen | Baclofen | 57 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 57 | 13 |
| Glipizide Er | Glipizide | 54 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 13 |
| Azithromycin | Azithromycin | 49 | 25 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 48 | 14 |
| Finasteride | Finasteride | 46 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 11 |
| Cephalexin | Cephalexin | 44 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 16 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 14 |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Azelastine Hcl | Azelastine Hcl | 36 | 16 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 17 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 28 |
| Donepezil Hcl | Donepezil Hcl | 33 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 30 | suppressed |
| Nystatin | Nystatin | 30 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 29 | suppressed |
| Celecoxib | Celecoxib | 26 | 13 |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | 12 |
| Fluconazole | Fluconazole | 24 | 11 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 13 |
| Glyburide | Glyburide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | 11 |
| Diazepam | Diazepam | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Betaseron | Interferon Beta-1b | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Pulmicort Flexhaler | Budesonide | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $77.69 · 4 records | PFIZER INC. | ABRYSVO, AREXVY, BOTOX, COMIRNATY, NURTEC ODT, PENBRAYA, PREVNAR 20, SHINGRIX, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error